Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Total Liabilities (2016 - 2025)

Marimed has reported Total Liabilities over the past 15 years, most recently at $137.8 million for Q4 2025.

  • Quarterly Total Liabilities rose 6.48% to $137.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $137.8 million through Dec 2025, up 6.48% year-over-year, with the annual reading at $137.8 million for FY2025, 6.48% up from the prior year.
  • Total Liabilities was $137.8 million for Q4 2025 at Marimed, up from $136.6 million in the prior quarter.
  • Over five years, Total Liabilities peaked at $137.8 million in Q4 2025 and troughed at $37.6 million in Q1 2021.
  • The 5-year median for Total Liabilities is $89.3 million (2023), against an average of $89.4 million.
  • Year-over-year, Total Liabilities tumbled 36.25% in 2021 and then surged 87.54% in 2023.
  • A 5-year view of Total Liabilities shows it stood at $49.2 million in 2021, then increased by 16.24% to $57.2 million in 2022, then skyrocketed by 87.54% to $107.2 million in 2023, then grew by 20.74% to $129.4 million in 2024, then rose by 6.48% to $137.8 million in 2025.
  • Per Business Quant, the three most recent readings for MRMD's Total Liabilities are $137.8 million (Q4 2025), $136.6 million (Q3 2025), and $131.2 million (Q2 2025).